I am desperately overweight but my doctor has banned me from Mounjaro. Is this right? DR ELLIE reveals the frightening jab health risk you can’t ignore – and why it’s got doctors worried
Mounjaro is a weight-loss drug known as a GLP-1 agonist, which tricks the body into thinking it is full.
🔮 Exponential View #552: ChatGPT turns three. New science, old economy. Meta eyes TPUs. GLP-1 headache, solarpunk & DeepSeek sans censorship++
Hi all, ChatGPT launched three years ago on this day. In that short time, access to “good enough” intelligence has grown massively. Generated using ChatGPT. I’ve spent a decade analysing the exponential age (I wrote a book about it in 2021), but these three years mark a distinct turn with overlapping S-curves in models and […]
Why you need a GLP-1 exit plan
I’ve seen clients start GLP-1 medications full of hope, and stop them feeling betrayed by their own biology. Some reached their limit with side effects: relentless nausea, fatigue, or the quiet loss of joy in eating. Others simply couldn’t afford to stay on. A few never saw the promised results at all. But for nearly […]
GLP-1 Drugs and AMD: What We’ve Learned So Far
(MedPage Today) — GLP-1 receptor agonists are being linked to a long list of benefits besides weight loss and diabetes, as evidence suggests they can lower the risk of conditions ranging from cancer and addiction to suicidal ideation, stroke…
Mechanisms of Glucagon‐Like Peptide 1 Receptor Agonist‐Induced Facial Lipodystrophy and a Path Toward Prevention
ABSTRACT Background The emergence of a distinct facial appearance characterized by pronounced hollowing of the cheeks, temples, chin, and periorbital region has become a noteworthy side effect of treatment with glucagon-like peptide 1 receptor agonists (GLP-1RAs). This phenomenon presents a growing concern in both dermatology and aesthetic medicine. The reduction of facial adipose tissue in […]
Tirzepatide’s benefits fade for most: Weight and health markers rebound after withdrawal, study finds
Eli Lilly and Company, along with partner institutions in the US and United Kingdom, describe how short-term pharmacologic intervention does not appear to have lasting effects for most tirzepatide patients. People with obesity who lost weight on tirzepatide often regained at least 25% of that loss within a year of stopping treatment, along with reversals in improvements in waist circumference, blood pressure, lipids, and glycemic measures.
The Download: the mysteries surrounding weight-loss drugs, and the economic effects of AI
This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology. What we still don’t know about weight-loss drugs Weight-loss drugs have been back in the news this week. First, we heard that Eli Lilly, the company behind Mounjaro and Zepbound, became the first […]
Weight-loss drug doesn’t reduce risk of Alzheimer’s – new studies
Vitalii Vodolazskyi/Shutterstock.com Semaglutide, the drug behind the blockbuster weight-loss jabs Ozempic and Wegovy, does not slow cognitive decline in people with early-stage Alzheimer’s, according to two large new studies. The results close the door, for now, on hopes that a treatment for diabetes and obesity might also help protect the brain. The evoke and evoke+ […]
The Era of Custom Weight-Loss Drugs Is Coming
“Ozempic is about to be old news,” my colleague Yasmin Tayag wrote in 2023, just before an even more powerful obesity drug, tirzepatide, then best known as Mounjaro, was approved. Well, two years later, Mounjaro is becoming old news, too. A whole slew of next-generation obesity drugs are on the horizon, some already advanced enough […]
IJMS, Vol. 26, Pages 11548: From Phytochemistry to Metabolic Regulation: The Insulin-Promoting Effects of Loureirin B Analogous to an Agonist of GLP-1 Receptor
IJMS, Vol. 26, Pages 11548: From Phytochemistry to Metabolic Regulation: The Insulin-Promoting Effects of Loureirin B Analogous to an Agonist of GLP-1 Receptor International Journal of Molecular Sciences doi: 10.3390/ijms262311548 Authors: Haowen Fang Xiaodong Sun Yanting Ding Siyuan Gu Bing Niu Qin Chen This study aimed to develop a potent, safe, and cost-effective small-molecule hypoglycemic […]